Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Onpattro (patisiran) for the Treatment of Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults

Drug Name

Onpattro™ (patisiran)

Developer

Alnylam Pharmaceuticals

Therapy Class

RNA interference (RNAi) therapy

Product Description

Lipid complex injection

Current Indication

Polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis

Market Sector

Genetics

Development Status

Approved in the US
Expand
Close
Close
Close

Go Top